REFRACTORY MULTIPLE MYELOMA
Clinical trials for REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Tough-to-Treat myeloma
Disease control CompletedThis early-phase study tested a combination of three drugs (selinexor, carfilzomib, and dexamethasone) in 52 adults with multiple myeloma that had returned or stopped responding to prior treatments. The main goal was to find the safest dose and identify side effects. Researchers …
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 17, 2026 02:08 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. The approach uses chemotherapy and radiation before donor stem cells are given, followed by drugs to prevent graft-versus-host disease. The goal was to control the cancer a…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug combo shows promise for hard-to-treat myeloma
Disease control CompletedThis study tested a combination of three drugs (pomalidomide, ixazomib, and dexamethasone) with or without a fourth drug (cyclophosphamide) in 66 adults with multiple myeloma that had come back or stopped responding to treatment. The goal was to see how well the drugs could contr…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for chinese patients with stubborn myeloma: experimental drug shows promise
Disease control CompletedThis study tested a new medicine, elranatamab, in 39 Chinese adults with multiple myeloma that stopped responding to several standard treatments. The drug works by helping the body's immune system attack the cancer cells. The goal was to see if the drug is safe and can shrink or …
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New hope for hard-to-treat myeloma: drug trio shows promise in early trial
Disease control CompletedThis early-phase study tested a combination of three drugs (ibrutinib, lenalidomide, and dexamethasone) in 14 adults with multiple myeloma that had returned or stopped responding to prior treatments. The main goal was to find safe doses and identify side effects. While the approa…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New antibody drug shows promise for Hard-to-Treat multiple myeloma
Disease control CompletedThis study tested a new drug called REGN5459 in 43 people with multiple myeloma that had returned or stopped responding to other treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals were to check safety and see if th…
Matched conditions: REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 11, 2026 20:37 UTC